Drugs / CART-PSMA-TGFβRDN cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03089203 | Mar 2017 → Sep 2038 expected | prostate cancer | University of Pennsylvania | Active not recruiting | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-PSMA-TGFβRDN cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03089203 ↗ |
| Action | Deplete | “the induction of tumor eradication in aggressive human prostate cancer mouse models” PMID 29807781 ↗ May 2018 |
| Modality | Cell therapy | “autologous CAR T cells” NCT03089203 ↗ |
| Route | Intravenous | “intravenously administered lentivirally transduced dual PSMA-specific/TGFβ-resistant CAR modified autologous T cells” NCT03089203 ↗ |